Sandra A Neargarder

Prof. Dr. Sandra A Neargarder

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in The Journals of Gerontology, Series B: Psychological Sciences and Social Sciences
Verified
Journal Article
Open access
PDF file
SNSandra A Neargarder
Sandra A Neargarder
ESErika R. Stone
Erika R. Stone
ACAlice Cronin-Golomb
Alice Cronin-Golomb
SOStephen Oross
Stephen Oross
Investigations of contrast sensitivity losses in Alzheimer's disease (AD) have yielded mixed findings, with some investigators reporting deficits and others not. Potential reasons for these discrepancies include differences between samples and assessments utilized and the failure of some investigators to account for acuity differences between groups. To investigate these issues, we administered four clinical contrast sensitivity assessments to the same group of AD patients and elderly control participants and examined the impact of acuity on performance for each assessment. Results revealed group differences across the spatial frequency range. Further, group acuity differences significantly affected performance on two of the four measures (the Regan and the Vistech but not on the Pelli-Robson or Freiburg assessments). Information regarding the availability of established age norms, test–retest reliability data, and other factors including the time, cost, and training needed to administer each measure is provided to aid clinicians and researchers in their search for an effective measure of contrast sensitivity.

1 March 2015 in Neuropsychologia
Verified
Journal Article
Closed access
MDMirella Díaz-Santos
Mirella Díaz-Santos
BCBo Cao
Bo Cao
AYArash Yazdanbakhsh
Arash Yazdanbakhsh
DNDaniel J. Norton
Daniel J. Norton
SNSandra A Neargarder
Sandra A Neargarder
ACAlice Cronin-Golomb
Alice Cronin-Golomb

1 January 2015 in Journal of Parkinson’s Disease
Verified
Journal Article
Closed access
PDF file
DSDaniel R. Seichepine
Daniel R. Seichepine
SNSandra A Neargarder
Sandra A Neargarder
SDSigurros Davidsdottir
Sigurros Davidsdottir
GRGretchen O. Reynolds
Gretchen O. Reynolds
ACAlice Cronin-Golomb
Alice Cronin-Golomb
Background/Objectives: Visuospatial problems are common in Parkinson's disease (PD) and likely stem from dysfunction in dopaminergic pathways and consequent disruption of cortical functioning. Characterizing the motor symptoms at disease onset provides a method of observing how dysfunction in these pathways influences visuospatial cognition. We examined two types of motor characteristics: Body side (left or right) and type of initial symptom (tremor or symptom other than tremor). Methods: 31 non-demented patients with PD, 16 with left-side onset (LPD) and 15 with right-side onset (RPD), as well as 17 healthy control participants (HC). The PD group was also divided by type of initial motor symptom, 15 having tremor as the initial symptom and 16 having an initial symptom other than tremor. Visuospatial function was assessed with the Clock Drawing Test. Results: Of the four Clock Drawing scoring methods used, the Rouleau method showed sensitivity to subgroup differences. As predicted, the LPD and non-tremor subgroups, but not the other subgroups, performed more poorly than the HC group. Conclusion: The findings provide further evidence for differences in cognition between these subtypes of PD and highlight the importance of considering disease subtypes when examining cognition.

1 June 2007 in Cognitive and Behavioral Neurology
Verified
Journal Article
Closed access
SNSandra A Neargarder
Sandra A Neargarder
MMMichael P. Murtagh
Michael P. Murtagh
BWBonnie Wong
Bonnie Wong
EHErin K. Hill
Erin K. Hill
To examine the neuropsychologic profile of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes) and relate it to neuropathologic findings. MELAS is one of over 40 mitochondrial disorders. Symptoms include seizures, strokelike episodes, headaches, memory impairment, hemianopsia, hearing loss, short stature, diffuse limb weakness, exercise intolerance, nausea, and vomiting. Age of onset ranges from 2 to 40 years. A hallmark of MELAS is normal development until the first symptoms appear. Because information regarding the neuropsychologic functioning of these individuals is sparse, we report findings from detailed neuropsychologic evaluations for a 13-year-old white male and a 33-year-old African-American male with MELAS. Results revealed global patterns of deterioration in executive function, attention, language, memory, visuospatial, and motor functioning. In both patients, brain scans revealed posterior pathology in the absence of frontal pathology. We compared our findings with other documented cases and concluded that MELAS is characterized by a pattern of global deterioration. This pattern differs from that observed in other mitochondrial disorders. The absence of identifiable frontal lobe pathology despite the presence of deficits in executive functioning may be related to the distribution patterns of deficient mitochondria and neuronal projection patterns.

1 September 2005 in Cognitive and Behavioral Neurology
Verified
Journal Article
Closed access
SNSandra A Neargarder
Sandra A Neargarder
ACAlice Cronin-Golomb
Alice Cronin-Golomb
To examine the role of visual characteristics of the target on Alzheimer disease (AD) patients' ability to detect change in naturalistic scenes. AD patients exhibit impairments in detecting changes in the visual environment. Unexamined to date is the influence of visual characteristics of the target on this ability. The change-detection experiment used 36 pairs of photographs of naturalistic scenes. Each pair was identical except for one target that differed in color, gray-scale, or presence/absence. Scene complexity also varied. The task was to locate the target; reaction times (RTs) were recorded. RTs increased as scene complexity increased. AD patients exhibited slower RTs than elderly adult controls (ECs), who were slower than young adults (N = 14/group). AD patients were unable to locate the target in 33.3% to 61.9% of the complex gray-scale trials, compared with 4.8% to 38.1% in the EC group. Performance on color and presence/absence trials was relatively good for all groups. The ability of AD patients to detect change in simulated real-world scenes is influenced by visual characteristics of the target and by scene complexity.

24 January 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SKShraddha B. Kinger
Shraddha B. Kinger
TJTruley Juneau
Truley Juneau
RKRini Kaplan
Rini Kaplan
CMCelina McDowell
Celina McDowell
JFJoshua T. Fox-Fuller
Joshua T. Fox-Fuller
ACAlice Cronin-Golomb
Alice Cronin-Golomb
Apathy, depression, and anxiety are common non-motor symptoms of Parkinson’s disease (PD). Tracking the changes in such symptoms over time would be valuable not only to determine their natural course during the disease, but also to establish the effects of unusual historical events interacting with the natural course. Having collected data on apathy (Apathy Scale), depression (Beck Depression Inventory-II), and anxiety (Parkinson’s Anxiety Scale) in a large sample of persons with PD (PwPD) before the beginning of the COVID-19 era, we followed up with these individuals to investigate the changes in their prevalence of apathy, depression, and anxiety across two timepoints (T1 and T2). Of the original 347 participants, 111 responded and provided complete data at T2. The data collection at T1, before COVID-19, occurred between 2017–2018. The data collection at T2 occurred in 2021 and included the same measures, with the addition of the Coronavirus Impact Scale to assess the effects of the pandemic on the individual participants. Over this period, there was a significant increase in apathy, but not in depression or anxiety. Anxiety and depression, but not apathy, were correlated with the impact of COVID-19.